Skip to main content
Log in

The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Background

While low-dose acetylsalicylic acid (ASA [aspirin]; 75–325 mg) is a mainstay of cardiovascular (CV) protection in patients at high risk of CV events, such protection may be compromised due to poor adherence (or discontinuation) resulting from gastrointestinal (GI) adverse events. To date, however, the link between GI adverse events and nonadherence to, and discontinuation of, low-dose ASA is not well established in the literature.

Objective

The aim of this study was to characterize the real-world impact of upper GI symptoms on low-dose ASA nonadherence and discontinuation in patients with CV risk taking low-dose ASA for CV protection.

Study Design

Multicenter, observational, noninterventional study.

Setting

Primary-care, cardiology, and practice group centers in the US, Canada, and France.

Patients

Subjects aged ≥18 years at risk of, or with confirmed, CV disease, and who had been prescribed or recommended low-dose ASA (75–325 mg daily) by a physician.

Main Outcome Measure

Adherence to low-dose ASA was assessed using 3 months of data prospectively collected using an electronic diary (completed at least three times/day). Adherence was defined as low-dose ASA intake of ≥75% over the 3-month eDiary phase. Discontinuation was defined as no reported low-dose ASA intake for ≥7 continuous days. The odds of daily adherence were calculated using a mixed-model analysis for repeated measures, and a Cox-proportional hazard model was used to assess the association between upper GI symptoms and time to discontinuation of low-dose ASA.

Results

Overall, 340 patients (mean age 50 years; 59% women) participated in the analysis. Most patients (75%) were low-dose ASA naíve at inclusion, and had not experienced upper GI symptoms within the previous 14 days. Among these patients, the onset of upper GI symptoms was rapid; symptoms were reported by 19% of patients on the first day of the study, rising to 46% of patients at the end of the first week. Over the 3-month study period, 18% of patients were nonadherent to low-dose ASA treatment. The occurrence of upper GI symptoms negatively affected low-dose ASA adherence, in both the overall patient population (odds ratio [OR] = 0.84; 95% CI 0.70, 1.0) and among patients who were low-dose ASA naíve at baseline (OR = 0.76; 95% CI 0.57, 1.0). A total of 13% of patients discontinued low-dose ASA therapy. For the overall cohort and for the low-dose ASA-naíve patients at baseline, more than three episodes of upper GI symptoms during the previous week was associated with an increased risk of low-dose ASA discontinuation compared with no episodes of upper GI symptoms during the previous week (hazard ratio [HR] = 2.60; 95% CI 1.00, 6.80, and HR = 7.52; 95% CI 2.57, 22.04, respectively).

Conclusions

Upper GI symptoms can lead to nonadherence to, and discontinuation of, low-dose ASA CV-protective therapy. Patients who initiate low-dose ASA may experience an early onset of upper GI symptoms. (Trial registration number: NCT00681759 [ClinicalTrials.gov Identifier]; AstraZeneca study code: D961FC00004)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Fig. 3
Fig. 4
Table III

Similar content being viewed by others

References

  1. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005 Dec 1; 353(22): 2373–83.

    Article  PubMed  CAS  Google Scholar 

  2. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004 Jan; 25(2): 166–81.

    Article  PubMed  Google Scholar 

  3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 May 30; 373(9678): 1849–60.

    Article  PubMed  Google Scholar 

  4. Herlitz J, Tóth PP, Næsdal J. Low-dose acetylsalicylic acid therapy for CV prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010; 10: 125–41.

    Article  PubMed  Google Scholar 

  5. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006 Nov; 27(22): 2667–74.

    Article  PubMed  Google Scholar 

  6. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005 May; 257(5): 399–414.

    Article  PubMed  CAS  Google Scholar 

  7. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005 Nov 1; 22(9): 795–801.

    Article  PubMed  CAS  Google Scholar 

  8. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002 Jan 15; 136(2): 161–72.

    PubMed  CAS  Google Scholar 

  9. Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008 Oct 1; 28(7): 878–85.

    PubMed  CAS  Google Scholar 

  10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348(9038): 1329–39.

    Article  Google Scholar 

  11. Glynn RJ, Buring JE, Manson JE, et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Arch Intern Med 1994 Dec 12–26; 154(23): 2649–57.

    Article  PubMed  CAS  Google Scholar 

  12. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol 2008; 4: 1–32.

    Article  PubMed  Google Scholar 

  13. Biondi-Zoccai G, Lotrionte M. Aspirin resistance in cardiovascular disease. BMJ 2008 Jan 26; 336(7637): 166–7.

    Article  PubMed  Google Scholar 

  14. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120(7): 631–5.

    Article  PubMed  CAS  Google Scholar 

  15. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006 Jan–Feb; 14(1): 18–25.

    Article  PubMed  Google Scholar 

  16. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008 Jan 26; 336(7637): 195–8.

    Article  PubMed  Google Scholar 

  17. Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol 2008 Oct; 33(9): 916–36; discussion 937–8.

    Article  Google Scholar 

  18. Lauritsen K, Degl’ Innocenti A, Hendel L, et al. Symptom recording in a randomised clinical trial: paper diaries vs. electronic or telephone data capture. Control Clin Trials 2004 Dec; 25(6): 585–97.

    Article  PubMed  Google Scholar 

  19. Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009 Jul 11; 374(9684): 119–25.

    Article  PubMed  CAS  Google Scholar 

  20. Scheiman JM, Van Rensburg CJ, Uebel P, et al. Prevention of low-dose acetylsalicylic acid-associated gastric/duodenal ulcers with esomeprazole 20 mg and 40 mg once daily in patients at increased risk of ulcer development: a randomized controlled trial (OBERON) [abstract]. Gastroenterology 2009; 136 (Suppl. 2): 412.

    Google Scholar 

  21. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008 Oct 28; 118(18): 1894–909.

    Article  PubMed  Google Scholar 

  22. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008 Sep 16; 52(12): 1038–9; author reply 1039.

    Article  PubMed  Google Scholar 

  23. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract]. Circulation 2008; 118(18): S815.

    Google Scholar 

  24. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar 31; 180(7): 713–8.

    Article  PubMed  Google Scholar 

  25. Dunn SP, Macauley T, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract]. Circulation 2008; 118(18): S815.

    Google Scholar 

  26. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 Jan 22; 360(4): 363–75.

    Article  PubMed  CAS  Google Scholar 

  27. Zairis M, Patsourakos N, Makrygiannis S, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting [abstract]. Eur Heart J 2008; 29 (Suppl.): 134.

    Google Scholar 

  28. Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry [abstract]. J Am Coll Cardiol 2009; 53 (10 Suppl. 1): 2903.

    Google Scholar 

  29. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 Jan 22; 51(3): 256–60.

    Article  PubMed  CAS  Google Scholar 

  30. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009 Sep 19; 374(9694): 989–97.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study is dedicated to Ola Junghard in recognition of his pivotal role in the design, analysis, and interpretation of the study, prior to his death in November 2009. This study was supported by AstraZeneca. We thank Anna Mett from inScience Communications, a Wolters Kluwer business, who provided medical writing support funded by AstraZeneca. Statistical analyses were conducted and validated by Eric Elkin (ICON Clinical Research, San Francisco, CA, USA) with programming support from Aimee Foreman, Ginny Lai, and Paul Frederick. Drs Næsdal and Sörstadius are employees of AstraZeneca. Drs Pratt, Thompson, and Elkin are each employees of clinical research companies that were contracted by AstraZeneca to provide research services for this study, and declare no further conflicts of interest that relate to this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen Pratt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pratt, S., Thompson, V.J., Elkin, E.P. et al. The Impact of Upper Gastrointestinal Symptoms on Nonadherence to, and Discontinuation of, Low-Dose Acetylsalicylic Acid in Patients with Cardiovascular Risk. Am J Cardiovasc Drugs 10, 281–288 (2010). https://doi.org/10.2165/11584410-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11584410-000000000-00000

Keywords

Navigation